Literature DB >> 19107366

Application of pulmonary venoplasty in the surgical treatment of lung cancer.

Xiangning Fu1, Ni Zhang, Yangkai Li, Wei Sun.   

Abstract

Presented in this study were three cases of lung cancer undergoing pulmonary venoplasty. In the 3 patients with central type of carcinoma of lung involving pulmonary vein, the main branch of right superior pulmonary vein and the distal end of the superior-lobe vein were occluded. The root part of the vein of right-middle lobe, plus part of vessel of of right superior vein was resected. The right superior vein was reconstructed by continuous 6-0 Prolene sutures. After the operation, the reconstructed was patent and the surgical margin was tumor-free. Postoperatively, clinical manifestations and plain chest films did not show any signs of venous blockade. The patients were discharged healed 3 weeks after the operation. The technical details of the surgery were presented, the improvements on the basis of traditional methods were discussed and its clinical application was evaluated. It is concluded that pulmonary venoplasty is a safe and feasible operation. Further improvement of the surgery will help conserve more lung tissue and benefit more patients because of expanded indications.

Entities:  

Mesh:

Year:  2008        PMID: 19107366     DOI: 10.1007/s11596-008-0615-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  3 in total

1.  BTS guidelines: guidelines on the selection of patients with lung cancer for surgery.

Authors: 
Journal:  Thorax       Date:  2001-02       Impact factor: 9.139

2.  [Pulmonary vein reconstruction for lung carcinoma].

Authors:  K Narita; H Iwanami; H Hiyoshi; M Tachibana; K Hasegawa; M Sakonji; E Tsuboi
Journal:  Kyobu Geka       Date:  1999-01

3.  Lung cancer surgery: the first 60 days. A population-based study.

Authors:  Hans Rostad; Trond-Eirik Strand; Anne Naalsund; Olaug Talleraas; Jarle Norstein
Journal:  Eur J Cardiothorac Surg       Date:  2006-03-07       Impact factor: 4.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.